Processa Pharmaceuticals, Inc.
PCSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.05 | 0.18 | 2.33 |
| FCF Yield | -16.63% | -3.68% | -2.17% | -0.46% |
| EV / EBITDA | -5.52 | -18.75 | -22.43 | -172.63 |
| Quality | ||||
| ROIC | -680.98% | -222.91% | -357.46% | -45.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.95 | 0.73 | 0.35 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -39.45% | 16.02% | -10.18% | -177.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 0.40 | 0.32 | 1.52 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -33,518.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |